ABSTRACT

Background: Alopecia areata is a rare but debilitating adverse effect of drugs used in the treatment of tremors. Recurrent hair loss after different types of tremor medications has never been described before.

Case Report: We herein report the case of a 56-year-old tremor patient who we diagnosed with tremor-dominant Parkinson’s disease. Unfortunately, she developed acute alopecia areata following the introduction of firstly levodopa/benserazide, secondly propranolol, and thirdly topiramate.

Discussion: Our case report highlights alopecia areata as a possible side effect to a variety of drugs commonly used for tremor management. Fortunately, in most reported cases, as well as in our case, the hair loss is reversible.
INTRODUCTION

Alopecia areata refers to the development of typical patches of hair loss, mainly from the scalp. This type of hair loss can be caused by a variety of medications, including several commonly used drugs for the treatment of tremors. Here we describe a unique case of a lady who unfortunately developed recurrent drug-induced alopecia after three different types of tremor medications.

CASE DESCRIPTION

A 56-year-old woman, with no relevant medical or family history, was referred to our movement disorders service for a two-year-history of progressive tremors in her left hand. She was not using any medications and denied using illicit agents. On examination, she demonstrated a coarse left upper limb tremor at rest, as well as with posture and action. Tone was normal but mild bradykinesia was found on the left side, with reduced arm swing while walking. \[^{18}\text{F-DOPA}\] PET/computed tomography (CT) showed reduced uptake in the right putamen (Figure 1) in keeping with a diagnosis of early-stage Parkinson’s disease and she was commenced on levodopa/benserazide.

Four weeks later, on a dose of 100/25 mg three times a day, she called in panic because of sudden severe hair loss on the right back of her head (see Figure 2a). Dopaminergic medication was ceased immediately. Laboratory investigations were completely normal and on dermatology review she was diagnosed with alopecia areata, based on the pattern and speed of her patchy bald lesions. There were no signs of another underlying auto-immune disease. The patient was commenced on combination therapy topical steroids/calcineurin inhibitors/minoxidil and after three months she noticed slow regrowth of hair on the scalp.

Half a year later, our patient described worsening of her tremors when holding cups. She had also experienced reduction after alcohol consumption, and we trialed her on propranolol therapy. Initially, she reported an 50%
improvement of tremulous movements, however, on a
dose of 40 mg per day, she developed significant patchy
hair loss again (see Figure 2b), causing us to cease the
beta-blocking agent. This time, regrowth occurred in a
couple of weeks, and in the light of the good response on
propranolol, we commenced her on a build-up scheme of
primidone. Despite an excellent effect on her tremors, she
had to be weaned off on a dose of 125 mg bi-daily because
of cognitive dysfunction and early hallucinations.

One year later, her tremors had extended to her left leg,
and after a long discussion we started her on a low dose
of topiramate, 50 mg daily. Unfortunately, within less than
two weeks the patient noticed first signs of alopecia on the
back side of the scalp (see Figure 2c) and after termination
of topiramate, regrowth occurred once more after a couple
of weeks.

DISCUSSION

Alopecia is a rare but debilitating side effect of various
drugs used in tremor treatment. The term is derived from
the Greek word for fox, “alopex,” and was so-named due to
fur loss seen in fox mange. In humans, it most commonly
affects the scalp resulting in patchy bald lesions, however
any hair-bearing area might be involved. The hair loss may
occur as a single, self-limiting episode or may reiterate at
varying intervals over many years. Some people might even
exhibit persistent bald areas and patches with regrowth
simultaneously.

The normal hair growth cycle consists of three stages.
The anagen phase refers to the period of 2–7 years of hair
growth, in which follicles produce the entire hair shaft from
tip to root. After a short transitional phase (catagen), hairs
enter the final telogen or resting phase for a few months. At
the end of this phase, the resting hairs fall out to allow new
hair to start growing in the follicles. Hair loss in alopecia
areata, has mostly been considered an immune-mediated
disorder due to a lymphocytic attack on the hair bulb,
although the exact pathophysiological mechanisms are
not fully understood. It may occur in association with other
auto-immune disorders (especially thyroid disorders) but
is also commonly seen after chemotherapy and radiation
[1]. Multiple drugs have been proposed as contributors for
this immune response as well. The inflammation is specific
for anagen hair, causing disruption of the growing phase
(anagen effluvium) resulting in sudden hair loss that occurs
within days or weeks. However, if the inhibitory influence is
removed, regrowth could happen quickly.

A second mechanism, telogen effluvium, describes
the shedding of hairs due to premature entry of anagen
follicles into the resting ‘telogen’ phase and can be caused
by stress, childbirth, along with many pharmaceuticals.

Medication-induced hair loss has sporadically been
described in Parkinson patients on levodopa [2] and other
forms of dopaminergic therapy [3, 4]. Except for one patient
with alopecia of the beard, all cases of dopaminergic-
induced hair loss occurred in women [5]. The fact that
dopamine-1 receptor transcripts are present in human
hair follicles is suggestive for a mediating role and a more
recent studies provided evidence for dopamine functioning
as catagen promoter, pushing hair follicles from the
anagen to the telogen phase, and causing regression of hair
growth [6]. However, the exact pathophysiological relation
between of dopamine and alopecia remains unclear.

Other drugs associated with alopecia include beta-
blocking agents. Propranolol is one of several beta-blockers
that can cause hair loss, however, given the widespread
clinical usage, cases have been rare [7]. The suggested
mechanism is a direct toxic effect on hair follicles [8]. The

Figure 2 Drug-induced Alopecia Areata after A) Levodopa, B) Propranolol, and C) Topiramate.
hair loss from propranolol is not permanent and is typically a result of telogen effluvium.

Cosmetic side effects, as is alopecia, are one of the most frequently reported side effect categories in anti-epileptic drugs (AED) and have a high intolerability rate. Hair loss has been described in valproate, carbamazepine, topiramate, phenytoin, phenobarbital, and clonazepam. Most cases have labelled telogen effluvium as the type of hair loss in AED, especially in patients taking valproate or carbamazepine [9]. Topiramate-induced alopecia is reported to occur in 1–2% of its users [10]. In most case reports, hair loss was reversible upon discontinuation or reduction of the dose. Recurrence of alopecia after reintroduction has also frequently been described.

Initially, our tremor patient developed alopecia areata after commencement of levodopa. After hair regrowth, both we and the patient, were reluctant to trial her on other forms of dopaminergic therapy and due to the significant action- and postural component of her tremors, we considered the possibility of a mixed tremor type (Parkinson’s tremor with essential tremor overlap). Therefore, our next step was to commence her on propranolol and later topiramate, but unfortunately alopecia reoccurred in both cases. The time duration between drug-introduction and onset of hair loss differed between four days to three months. For all three medications, hair loss was reversible after discontinuation and regrowth occurred in a few weeks. No other causes for alopecia were found. After cessation of topiramate, she decided to withhold from further medication options. As her tremors have worsened, she is currently under consideration for Deep Brain Stimulation surgery.

Alopecia areata is a significant adverse effect of different types of medication used in the treatment of tremors and can have a negative impact on emotional well-being and social functioning. Fortunately, in most cases, as well as in our patient, the hair loss is reversible after reduction or cessation of the causing agent.

ETHICS AND CONSENT

A. Statement of Human and Animal Rights:
The authors confirm that the approval of an institutional review board was not required for this work. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. The patient gave written informed consent for collection and publication of her data.

B. Statement of Informed Consent:
The patient gave written consent for publication.

COMPETING INTERESTS

The authors have no competing interests to declare.

AUTHOR CONTRIBUTIONS

TL received support from the Jan Meerwaldt Foundation for an Overseas Fellowship. AL reports no disclosures.

AUTHOR AFFILIATIONS

Tjerk J. Lagrand, MD  orcid.org/0000-0002-4967-866X
Department of Neurology, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia

Alexander C. Lehn, MD  orcid.org/0000-0003-3551-7010
Department of Neurology, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia; University of Queensland, Brisbane, Queensland, Australia

REFERENCES

1. Thomas EA, Kadyan RS. Alopecia areata and autoimmunity: a clinical study. Indian J Dermatol. 2008; 53(2): 70–74. DOI: https://doi.org/10.4103/0019-5154.41650
2. Marshall A, Williams MJ. Alopecia and levodopa. Br Med J. 1971; 2(5752): 47. DOI: https://doi.org/10.1136/bmj.2.5752.47
3. Katz KA, Cotsarelis G, Gupta R, Seykora JT. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson’s disease. J Am Acad Dermatol. 2006; 55(S SUPPL.): 103–104. DOI: https://doi.org/10.1016/j.jaad.2005.09.039
4. Grauer MT, Sieb JP. Alopecia induced by dopamine agonists [4]. Neurology. 2002; 59(12): 2012. DOI: https://doi.org/10.1212/WNL.59.12.2012
5. Miwa H, Kondo T. Hair loss induced by dopamine agonist: Case report and review of the literature. Park Relat Disord. 2003; 10(1): 51–52. DOI: https://doi.org/10.1016/S1353-8020(03)00058-0
6. Langan EA, Lisztes E, Bíro T, et al. Dopamine is a novel, direct inducer of catagen in human scalp hair follicles in vitro. Br J Dermatol. 2013; 168(3): 520–525. DOI: https://doi.org/10.1111/bjd.12113
7. Scribner MD. Propranolol Therapy. Arch Dermatol. 1977; 113(Sept): 1303. DOI: https://doi.org/10.1001/archderm.1977.01640091515103
8. Fraunfelder FT, Meyer SM, Menacker SJ. Alopecia possibly secondary to topical ophthalmic beta-blockers. JAMA. 1990; 263(11): 1493–1494. DOI: https://doi.org/10.1001/jama.1990.03440110055020
9. Pillans PJ, Woods DJ. Drug-associated alopecia. Int J Dermatol. 1995; 34(3): 149–158. DOI: https://doi.org/10.1111/j.1365-4362.1995.tb01556.x

10. Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann Clin Psychiatry. 2000; 12(1): 35–42. DOI: https://doi.org/10.1023/A:1009074926921